Welcome to our dedicated page for Dermata Therapeutics news (Ticker: DRMAW), a resource for investors and traders seeking the latest updates and insights on Dermata Therapeutics stock.
The Dermata Therapeutics, Inc. (DRMA, DRMAW) news page on Stock Titan aggregates company-issued updates, clinical milestones, financing announcements, and regulatory disclosures related to its dermatology-focused business. Dermata describes itself as a science-driven leader in dermatologic solutions built around its proprietary Spongilla technology platform, with programs in acne, hyperhidrosis, and other skin diseases and aesthetic applications.
Recent news highlights Dermata’s strategic pivot from prescription dermatology development to over-the-counter (OTC) pharmaceutical skin treatments that can be sold directly to consumers. Company press releases and an accompanying Form 8-K explain that Dermata is prioritizing an OTC once-weekly acne kit that combines an active ingredient from the OTC acne monograph with its Spongilla technology, with launch preparations involving branding, packaging, manufacturing, and consumer research.
News items also cover clinical and scientific developments, such as positive topline data from the Phase 3 STAR-1 trial of XYNGARI™ in moderate-to-severe acne, additional data presentations at international dermatology congresses, and collaboration activities around DMT410 for topical botulinum toxin delivery in hyperhidrosis and aesthetic indications. Financing-related releases describe private placements and warrant transactions intended to fund operations and OTC product launch activities, while other notices address Nasdaq listing compliance and corporate actions like a reverse stock split.
Investors and observers can use this news feed to follow Dermata’s progress in OTC dermatology, updates on its Spongilla-based acne kit, developments in its DMT410 program, intellectual property milestones, and material events reported in 8-K filings. Bookmark this page to review Dermata’s historical and ongoing disclosures as it advances its dermatology strategy.
Dermata (Nasdaq:DRMA) received notice of acceptance from the Australian Patent Office for Australian Patent Application No. 2020315876, covering topical delivery of dermal fillers using its Bioneedle Delivery System (BDS). The patent will be automatically issued three months after acceptance unless a third party files an opposition.
The acceptance would be Dermata's first patent, if issued, for BDS with dermal fillers and adds to existing allowed and issued BDS patents for botulinum toxin in the US, Australia, and Japan. The company noted a strategic shift to selling direct to skincare professionals.
Dermata Therapeutics (Nasdaq:DRMA) announced a strategic pivot to develop and commercialize direct-to-consumer skincare under the new brand Tome, planning to launch its first product, the Foundational Treatment, in mid-2026. The company reported year-end 2025 cash of $7.5 million and raised $15.4 million in gross proceeds during 2025 and early 2026, which it expects will fund operations into the first quarter of 2027. Dermata also noted a $5.3 million reduction in R&D spending versus 2024 following completion of the STAR-1 acne study and withdrew its IND for XYNGARI to focus on the DTC strategy.
Dermata (Nasdaq:DRMA) appointed Kyra Peckaitis as Vice President, Marketing to lead the launch of the new Tome skincare brand, with first commercial products expected in mid-2026. Ms. Peckaitis began March 9, 2026 and received a non-qualified option for 15,000 shares at an exercise price of $1.33 per share.
The option vests 25% after one year, then monthly over 36 months, and was granted outside the company’s shareholder-approved equity incentive plan as a board-approved inducement under Nasdaq Listing Rule 5635(c)(4).
Dermata (Nasdaq:DRMA) unveiled Tome, a consumer-facing skincare brand positioning itself as "skintech at home." The company plans to launch its first Tome product, an over-the-counter once-weekly acne and resurfacing treatment, in mid-2026. Tome is described as "Studied Skincare™," combining timeless natural ingredients with modern innovations and dermatologist study to deliver high-potency, prescription-like results without prescriptions.
The announcement frames this as a strategic shift toward direct-to-consumer products intended to become foundational in simple weekly routines for improving overall skin quality.
Dermata (NASDAQ:DRMA) announced the Australian Patent Office granted Australian Patent No. 2019419387 for its Spongilla technology combination as a method to treat acne on January 20, 2026. This follows an already-issued U.S. patent covering the same technology. Dermata plans to launch a once-weekly, over-the-counter acne treatment system incorporating Spongilla in mid-2026 in the U.S. The company said the granted patent strengthens its global intellectual property estate, with additional patent filings pending in other jurisdictions and Australia cited as a key future market.
Dermata Therapeutics (Nasdaq:DRMA / DRMAW) closed a private placement priced at-the-market, issuing 2,022,062 shares (or pre-funded warrants) and accompanying series C and series D warrants at $2.04 per share (or pre-funded warrant).
Gross proceeds were approximately $4.1 million upfront, with up to $8.3 million of additional gross proceeds possible if warrants are fully exercised. Series C warrants expire five years after stockholder approval; series D warrants expire 24 months after approval. The company amended prior warrants covering 120,734 shares, lowering the exercise price to $2.04. Insiders participated; H.C. Wainwright acted as placement agent. Proceeds are planned for general corporate purposes and product launch activities.
Dermata Therapeutics (NASDAQ:DRMA / DRMAW) announced a private placement to issue 2,022,062 shares (or pre-funded warrants) plus series C and short-term series D warrants at $2.04 per share, providing approximately $4.1 million of gross proceeds upfront and up to ~$8.3 million additional if warrants are fully exercised (total ~$12.4 million). Series C warrants expire five years; series D warrants expire 24 months; warrant exercises and amended warrants are subject to stockholder approval. Closing expected on or about December 29, 2025. Company insiders, including the CEO and CFO, are participating. H.C. Wainwright is placement agent. Net proceeds for general corporate purposes and OTC acne kit activities.
Dermata Therapeutics (NASDAQ:DRMA) announced it will unveil a new brand identity for its over-the-counter skincare business in the coming weeks, positioning the unit as a "science-first" consumer skincare brand that blends ancestral remedies with clinical innovation. The company said the identity reflects a mission to deliver potent, health-forward products and will frame therapies and technologies through quantifiable performance.
Dermata plans to launch its first OTC once-weekly acne kit in mid-2026 and will release visual assets, product positioning, and phased launch communications over the coming months.
Dermata Therapeutics (Nasdaq: DRMA) announced a strategic pivot to develop and commercialize over-the-counter dermatology products and reported Q3 2025 results. The company plans to launch a once-weekly acne kit using its Spongilla technology in mid-2026 and is developing branding, packaging, and manufacturing for direct-to-consumer and professional sales.
Recent clinical progress includes positive topline Phase 3 STAR-1 results that met all three primary endpoints and showed separation from placebo by week 4. As of September 30, 2025, Dermata had $4.7 million in cash and expects funding into Q2 2026.
Dermata Therapeutics (NASDAQ:DRMA) announced the acceptance of its patent application by the Australian Patent Office for its Spongilla technology combination to treat acne. The patent, which follows a similar U.S. patent issuance, will automatically be granted in mid-January 2026 unless opposed.
The company plans to launch a once-weekly, Over-the-Counter (OTC) pharmaceutical acne kit incorporating its Spongilla technology by mid-2026. This innovative treatment targets underlying acne mechanisms with enhanced precision, potentially offering improved outcomes and reduced side effects. The Australian market represents a significant opportunity with over 3.3 million people diagnosed with acne.